阿尔凯默斯(ALKS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALKS 阿尔凯默斯

盘前交易 05-13 09:25:42 EDT

38.29

+2.82

+7.95%

盘前38.58

+0.29+0.76%

09:23 EDT

最高38.46	最低35.51	成交量402.67万
今开36.00	昨收35.47	日振幅8.32%
总市值63.81亿	流通市值62.19亿	总股本1.67亿
成交额1.51亿	换手率2.48%	流通股本1.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALKS","market":"US","secType":"STK","nameCN":"阿尔凯默斯","latestPrice":38.29,"timestamp":1778616000000,"preClose":35.47,"halted":0,"volume":4026681,"hourTrading":{"tag":"盘前","latestPrice":38.5798,"preClose":38.29,"latestTime":"09:23 EDT","volume":1226,"amount":47141.232500000006,"timestamp":1778678603470,"change":0.2898,"changeRate":0.007569,"amplitude":0.016976},"delay":0,"changeRate":0.07950380603326757,"floatShares":162415981,"shares":166649934,"eps":0.909465,"marketStatus":"盘前交易","change":2.82,"latestTime":"05-13 09:25:42 EDT","open":36,"high":38.46,"low":35.51,"amount":151024617.05238,"amplitude":0.083169,"askPrice":39.93,"askSize":200,"bidPrice":36.97,"bidSize":168,"shortable":3,"etf":0,"ttmEps":0.909465,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778679000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":38.29,"preHourTrading":{"tag":"盘前","latestPrice":38.5798,"preClose":38.29,"latestTime":"09:23 EDT","volume":1226,"amount":47141.232500000006,"timestamp":1778678603470,"change":0.2898,"changeRate":0.007569,"amplitude":0.016976},"postHourTrading":{"tag":"盘后","latestPrice":38,"preClose":38.29,"latestTime":"19:44 EDT","volume":90267,"amount":3456264.2996,"timestamp":1778629445473,"change":-0.29,"changeRate":-0.007574,"amplitude":0.010969},"volumeRatio":1.5967277297418172,"impliedVol":0.061,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/ALKS/tweets","defaultTab":"tweets","newsList":[{"id":"1145115986","title":"异动解读 | 阿尔凯默斯盘中大涨6.37%，因Lumryz®三期研究获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145115986","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145115986?lang=zh_cn&edition=full","pubTime":"2026-05-13 02:21","pubTimestamp":1778610087,"startTime":"0","endTime":"0","summary":"阿尔凯默斯（ALKS）今日盘中股价大涨6.37%，引起了市场的广泛关注。消息面上，阿尔凯默斯宣布其针对特发性嗜睡症成人患者的Lumryz®（羟丁酸钠）缓释制剂，在关键性3期研究中取得了积极的顶线结果。初步数据显示，与安慰剂相比，Lumryz®达到了预设的主要疗效终点，显示出统计学上的显著改善，且安全性特征与已知信息一致。这一积极结果标志着阿尔凯默斯在睡眠障碍治疗领域取得了重要进展，为公司后续向监管机构提交新药申请奠定了基础，从而增强了投资者对公司未来前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139295905","title":"阿尔凯默斯公布Lumryz®治疗特发性嗜睡症的3期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139295905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139295905?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:05","pubTimestamp":1778583913,"startTime":"0","endTime":"0","summary":"阿尔凯默斯宣布，其针对特发性嗜睡症成人患者的Lumryz®（羟丁酸钠）缓释制剂，在名为Revitalyz℠的关键性3期研究中取得了积极的顶线结果。这项研究评估了该药物在改善患者日间过度嗜睡症状方面的有效性与安全性。初步数据显示，与安慰剂相比，Lumryz®达到了预设的主要疗效终点，显示出统计学上的显著改善。安全性特征与药物已知信息一致，未发现新的安全问题。这一积极结果标志着阿尔凯默斯在睡眠障碍治疗领域取得了重要进展，为公司后续向监管机构提交新药申请奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454353","title":"财报前瞻｜阿尔凯默斯本季度营收预计增18.33%，机构观点偏空","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454353","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164454353?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:11","pubTimestamp":1777349480,"startTime":"0","endTime":"0","summary":"阿尔凯默斯将于2026年05月05日美股盘前发布最新季度财报，市场关注收入回升与利润承压的取舍及研发进展节奏。市场一致预期本季度阿尔凯默斯营收为3.60亿美元，同比增18.33%；调整后每股收益为-0.57美元，同比-341.85%；息税前利润为-9,576.29万美元，同比-1,773.81%，公司上一季度披露的是全年指引，未提供本季度毛利率与净利润或净利率的明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜阿尔凯默斯本季度营收预计增18.33%，机构观点偏空","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117201237","title":"阿尔凯默斯将在2026年美国神经病学学会年会上公布阿立索瑞通治疗1型发作性睡病的Vibrance-1二期研究补充数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1117201237","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117201237?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:03","pubTimestamp":1776337383,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司宣布，将于2026年美国神经病学学会（AAN）年度会议上，展示其候选药物阿立索瑞通（Alixorexton）针对1型发作性睡病患者的Vibrance-1二期临床试验的补充数据集。\n此次公布的数据将提供关于阿立索瑞通疗效与安全性的更深层次见解，进一步阐明该疗法在管理1型发作性睡病核心症状方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183301439","title":"长期研究结果揭示Lybalvi®对精神分裂症阴性症状的疗效，发表于《临床精神病学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1183301439","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183301439?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:01","pubTimestamp":1776164490,"startTime":"0","endTime":"0","summary":"一项针对利巴维®（奥氮平和萨米多芬）对精神分裂症阴性症状影响的长期分析结果，近日在权威学术期刊《临床精神病学杂志》上正式发表。该研究提供了关于此药物长期疗效的重要临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624519909","title":"从减肥药加码睡眠障碍！礼来拟以最高78亿美元收购Centessa，进军发作性睡病及觉醒障碍治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2624519909","media":"华尔街见闻","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624519909?lang=zh_cn&edition=full","pubTime":"2026-04-01 21:20","pubTimestamp":1775049617,"startTime":"0","endTime":"0","summary":"礼来宣布以最高78亿美元收购Centessa，进军发作性睡病及觉醒障碍治疗领域。此举填补了其在失眠领域的布局空白，是中枢神经系统扩张战略的延续。食欲素类药物潜在市场远超睡眠障碍，有望延伸至神经退行性疾病、ADHD等更广泛领域，打开数十亿美元想象空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3769013","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999013999.USD","IE00B1BXHZ80.USD","LU0109391861.USD","LU1629891620.HKD","IE00BFSS8Q28.SGD","LU2168564495.EUR","SG9999014880.SGD","IE00BK4W5M84.HKD","LU0198837287.USD","LU1061106388.HKD","IE0004445015.USD","LU1127390331.HKD","SG9999014898.SGD","LU2028103732.USD","SG9999015986.USD","LU2237443978.SGD","LU2089984988.USD","LU2237443382.USD","LU0683600562.USD","IE0001KFT4U8.USD","SG9999014914.USD","IE00BKPKM429.USD","LU0109394709.USD","LU2264538146.SGD","LU1093756168.USD","ELIL","LU2108987350.USD","IE0009355771.USD","IE00B2B36J28.USD","BK4588","LU0353189680.USD","IE00BN29S564.USD","LU2023250504.SGD","LU1291159041.SGD","LU0964807845.USD","LU0353189763.USD","ALKS","IE00BFTCPJ56.SGD","SGXZ99366536.SGD","SG9999018865.SGD","LU0786609619.USD","LU0471298694.HKD","LU0122379950.USD","LU0456855351.SGD","LLY","LU1069344957.HKD","LU1804176565.USD","BK4007","BK4585","LU0823434583.USD","LU2602419157.SGD","LU2361044865.SGD","IE00BFSS7M15.SGD","LU0106261372.USD","IE00BK4W5L77.USD","LU0158827948.USD","LU0708995401.HKD","LU2471134796.USD","LU1064131342.USD","SGXZ51526630.SGD","LU0061475181.USD","LU2756315664.SGD","LU0323591593.USD","LU2168563687.JPY","LU2552382215.SGD","LU1548497426.USD","LU1035775433.USD","LU0820562030.AUD","LU2168564222.USD","LU0289739699.SGD","BK4599","BK4581","LU2168564149.EUR","LU0385154629.USD","LU2491049909.HKD","LU0354030438.USD","LU2087625088.SGD","LU1720051017.SGD","LLYX","LU1267930730.SGD","LU1868836591.USD","LU2089284900.SGD","SG9999017495.SGD","LU2756315318.SGD","IE0004445239.USD","LU0256863811.USD","IE0002141913.USD","LU2324357040.USD","LU0256863902.USD","LU0097036916.USD","LU2896262040.SGD","LU1712237335.SGD","LU2471134952.CNY","LU0432979614.USD","LU0225283273.USD","LU2211815571.USD","SG9999001176.SGD","IE00B4R5TH58.HKD","LU2237443895.HKD","LU2461242641.AUD","LU2111349929.HKD","LU2112291526.USD","IE00BKDWB100.SGD","LU2417539215.USD","SGXZ57979304.SGD","LU1280957306.USD","LU2471134523.USD","LU0203202063.USD","LU0889565916.HKD","LU0114720955.EUR","LU1974910355.USD","IE00BJJMRZ35.SGD","LU1988902786.USD","LU0234572021.USD","LU1989771016.USD","LU2063271972.USD","LU2491050071.SGD","LU2271345857.HKD","LU0672654240.SGD","LU0823434740.USD","IE00BWXC8680.SGD","LU1093756325.SGD","LU1057294990.SGD","LU2750360641.GBP","LU2023251221.USD","LU0820561818.USD","LU0266013472.USD","IE00BJLML261.HKD","BK4516","LU0320765059.SGD","SG9999001176.USD","LU0210536198.USD","SG9999014906.USD","LU2265009873.SGD","LU0058720904.USD","LU1868837300.USD","LU2237443465.HKD","BK4534","SG9999015978.USD","LU0094547139.USD","IE00B7KXQ091.USD","LU1623119135.USD","IE00B4JS1V06.HKD","LU2089283258.USD","LU1917777945.USD","IE0005OL40V9.USD","IE00BJT1NW94.SGD","LU0466842654.USD","LU0820561909.HKD","LU0882574055.USD","LU1232071149.USD","SGXZ31699556.SGD","LU0354030511.USD","LU2361045086.USD","LU1023059063.AUD","IE00B775H168.HKD","LU1814569148.SGD","LU1720051108.HKD","LU2746668461.USD","GB00BDT5M118.USD","LU1868836914.USD","LU2168564065.EUR","LU2750360997.AUD","LU2237438978.USD","LU1551013342.USD","LU2023250330.USD","LU0417517546.SGD","LU1551013425.SGD","LU2468319806.SGD","BK4533","LU2456880835.USD","LU0823416689.USD","LU0320765992.SGD","LU0238689110.USD","LU0079474960.USD","LU1868837136.USD","IE00B1XK9C88.USD","LU2357305700.SGD","LU2746668974.SGD","LU2236285917.USD","LU2552382058.USD","LU0316494557.USD","SG9999015952.SGD","LU2106854487.HKD","LLYZ","CNTA","LU0203201768.USD","LU0006306889.USD","LU2462157665.USD","LU0882574139.USD","LU2552382132.HKD","LU0943347566.SGD","LU2237443549.SGD","LU0471298777.SGD","LU0689472784.USD","LU2213496289.HKD","LU2237443622.USD","LU1868836757.USD","LU2471134879.HKD","LU0158827781.USD","LU1145028129.USD","LU2361044949.HKD","IE00BJJMRX11.SGD","LU2360106947.USD","LU1366192091.USD","LU1983299246.USD","LLII","LU2491050154.USD","SG9999018857.SGD","LU0640476718.USD","LU1323610961.USD","IE00BJJMRY28.SGD","SGXZ81514606.USD","LU0787776722.HKD","LU0096364046.USD","SG9999015945.SGD","ELIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143078608","title":"阿尔凯默斯启动评估Alixorexton治疗1型与2型发作性睡病的第三阶段Brilliance研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1143078608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143078608?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:01","pubTimestamp":1775041272,"startTime":"0","endTime":"0","summary":"阿尔凯默斯宣布，已正式启动其第三阶段Brilliance临床试验项目，旨在评估其在研药物Alixorexton针对1型与2型发作性睡病的治疗效果。这项关键研究的启动标志着该药物研发进程迈入重要阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621761686","title":"阿尔凯默斯在印度推出司美格鲁肽注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=2621761686","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621761686?lang=zh_cn&edition=full","pubTime":"2026-03-21 15:02","pubTimestamp":1774076543,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNDmain","BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616827305","title":"阿尔凯默斯2025财年实现净利润2.42亿美元，同比减少34.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616827305","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616827305?lang=zh_cn&edition=full","pubTime":"2026-03-01 00:00","pubTimestamp":1772294459,"startTime":"0","endTime":"0","summary":"3月1日，阿尔凯默斯公布财报，公告显示公司2025财年净利润为2.42亿美元，同比减少34.95%；其中营业收入为14.76亿美元，同比减少5.26%，每股基本收益为1.47美元。从资产负债表来看，阿尔凯默斯总负债7.11亿美元，其中短期债务6.75百万美元，资产负债比为3.56，流动比率为3.56。机构评级：截至2026年3月1日，当前有17家机构对阿尔凯默斯目标价做出预测，其中目标均价为43.65美元，其中最低目标价为30.00美元，最高目标价为58.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301000114a43b969b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301000114a43b969b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114027072","title":"异动解读 | 财报及指引不及预期，阿尔凯默斯盘中大跌5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114027072","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114027072?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:49","pubTimestamp":1772030993,"startTime":"0","endTime":"0","summary":"阿尔凯默斯（ALKS）今日盘中股价大跌5.35%，引发了市场关注。消息面上，该公司在盘前公布了截至2025年12月31日的第四季度及全年财务报告，并同时提供了2026财年的财务业绩指引。市场分析认为，此次股价下跌很可能与财报数据或未来业绩展望未达到投资者预期有关。作为一家生物制药企业，阿尔凯默斯的财务表现和增长前景一直是市场关注的焦点，此次业绩发布后的市场反应，反映了投资者对公司短期盈利能力和长期发展路径的重新评估。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160279616","title":"阿尔凯默斯公布2025财年第四季度及全年业绩 并展望2026年财务预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1160279616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160279616?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:06","pubTimestamp":1772021172,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司已正式披露其截至2025年12月31日的第四季度及全年财务报告。与此同时，这家生物制药企业还向市场提供了针对2026财年的财务业绩指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614729287","title":"阿尔凯默斯盘中异动 下午盘股价大涨5.03%报33.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614729287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614729287?lang=zh_cn&edition=full","pubTime":"2026-02-25 03:18","pubTimestamp":1771960713,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日03时18分，阿尔凯默斯股票出现异动，股价大幅上涨5.03%。截至发稿，该股报33.81美元/股，成交量120.429万股，换手率0.73%，振幅3.87%。最近的财报数据显示，该股实现营业收入3.94亿美元，净利润82.76百万美元，每股收益0.50美元，毛利3.41亿美元，市盈率16.81倍。阿尔凯默斯股票所在的制药行业中，整体跌幅为0.48%。阿尔凯默斯从第三方购买活性药物产品或者从其第三方被许可方那里获得活性药物产品，以使用其技术配制产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225031833a71ae9df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225031833a71ae9df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198331213","title":"财报前瞻｜阿尔凯默斯本季度营收预计小幅增长，并购推进睡眠线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1198331213","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198331213?lang=zh_cn&edition=full","pubTime":"2026-02-18 11:37","pubTimestamp":1771385874,"startTime":"0","endTime":"0","summary":"阿尔凯默斯将于2026年02月25日发布最新季度财报，市场关注收入韧性与利润承压的权衡及并购整合进展。综合近期可得的机构前瞻评论与市场讨论，看空观点在比例上略占优势：核心依据在于本季度一致预期指向调整后每股收益同比下降58.31%、息税前利润同比下降52.25%，而收入仅小幅增长0.56%，利润弹性阶段性走弱。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜阿尔凯默斯本季度营收预计小幅增长，并购推进睡眠线布局","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146257464","title":"阿尔凯默斯完成收购Avadel制药，加速进军睡眠药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1146257464","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146257464?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:30","pubTimestamp":1770899415,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司（Alkermes PLC）已顺利完成对Avadel制药公司（Avadel Pharmaceuticals plc）的收购。这一战略性举措显著加速了该公司进入睡眠药物市场的步伐，为其产品管线注入了新的活力。\n通过本次收购，阿尔凯默斯进一步巩固了其在专科制药领域的布局，并有望借助Avadel制药在睡眠障碍治疗方面的专长，开拓新的增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALKS","BK4139","AVDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103775048","title":"H Lundbeck a/S：我们对收购Avadel的报价已不再被其董事会视为优越，我们正在考虑我们的选项","url":"https://stock-news.laohu8.com/highlight/detail?id=1103775048","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103775048?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:10","pubTimestamp":1763557811,"startTime":"0","endTime":"0","summary":"H Lundbeck a/S：我们对收购Avadel的报价已不再被其董事会视为优越，我们正在考虑我们的选项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALKS","BK4139","AVDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108424260","title":"阿尔凯默斯：拟议交易考虑包括21.00美元现金及一份不可转让的CVR，可能额外支付1.50美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=1108424260","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108424260?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:06","pubTimestamp":1763550362,"startTime":"0","endTime":"0","summary":"阿尔凯默斯：拟议交易考虑包括21.00美元现金及一份不可转让的CVR，可能额外支付1.50美元/股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123510586","title":"阿尔凯默斯：Avadel董事会确认阿尔凯默斯的增值要约中的CVR条款优于Lundbeck提案中的CVR条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1123510586","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123510586?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:03","pubTimestamp":1763550191,"startTime":"0","endTime":"0","summary":"阿尔凯默斯：Avadel董事会确认阿尔凯默斯的增值要约中的CVR条款优于Lundbeck提案中的CVR条款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVDL","BK4007","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118351394","title":"Avadel Pharmaceuticals：根据与阿尔凯默斯的协议，公司与阿尔凯默斯可以在5个工作日内就现有交易进行潜在调整的谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=1118351394","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118351394?lang=zh_cn&edition=full","pubTime":"2025-11-17 18:47","pubTimestamp":1763376431,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals：根据与阿尔凯默斯的协议，公司与阿尔凯默斯可以在5个工作日内就现有交易进行潜在调整的谈判","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVDL","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158870088","title":"阿尔凯默斯公布Vibrance-2二期研究的积极初步结果，阿利克索伦每日一次治疗2型嗜睡症","url":"https://stock-news.laohu8.com/highlight/detail?id=1158870088","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158870088?lang=zh_cn&edition=full","pubTime":"2025-11-15 23:36","pubTimestamp":1763220993,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公布Vibrance-2二期研究的积极初步结果，阿利克索伦每日一次治疗2型嗜睡症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511608563","title":"阿尔凯默斯2024财年实现净利润3.72亿美元，同比减少28.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511608563","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511608563?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:01","pubTimestamp":1739635282,"startTime":"0","endTime":"0","summary":"2月16日，阿尔凯默斯公布财报，公告显示公司2024财年净利润为3.72亿美元，同比减少28.32%；其中营业收入为15.58亿美元，同比减少6.31%，每股基本收益为2.22美元。机构评级：截至2025年2月16日，当前有12家机构对阿尔凯默斯目标价做出预测，其中目标均价为38.58美元，其中最低目标价为30.00美元，最高目标价为46.00美元。阿尔凯默斯从第三方购买活性药物产品，或者从第三方被许可方处获得活性药物产品，利用其技术配制产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000145a24729ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000145a24729ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alkermes.com","stockEarnings":[{"period":"1week","weight":0.0563},{"period":"1month","weight":0.1478},{"period":"3month","weight":0.0968},{"period":"6month","weight":0.2348},{"period":"1year","weight":0.2245},{"period":"ytd","weight":0.3685}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alkermes Public Limited Company于2011年5月4日在爱尔兰成立为一家私人有限公司，名称为Antler Science Two Limited（注册号498284）。该公司是一家完全整合的全球性生物制药公司，利用其科学专长和专有技术开发创新药物，改善患者的治疗效果。公司拥有多元化的产品组合，包括20多种商业药物产品和大量临床候选产品，用于治疗中枢神经系统疾病，如成瘾、精神分裂症和抑郁症。","yearOnYearQuotes":[{"month":1,"riseRate":0.771429,"avgChangeRate":0.090924},{"month":2,"riseRate":0.428571,"avgChangeRate":0.050544},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.039697},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.029255},{"month":5,"riseRate":0.571429,"avgChangeRate":0.054239},{"month":6,"riseRate":0.470588,"avgChangeRate":0.00341},{"month":7,"riseRate":0.529412,"avgChangeRate":0.023052},{"month":8,"riseRate":0.485714,"avgChangeRate":0.043862},{"month":9,"riseRate":0.428571,"avgChangeRate":0.001956},{"month":10,"riseRate":0.514286,"avgChangeRate":0.03285},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.011873},{"month":12,"riseRate":0.685714,"avgChangeRate":0.05445}],"exchange":"NASDAQ","name":"阿尔凯默斯","nameEN":"Alkermes PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔凯默斯(ALKS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔凯默斯(ALKS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔凯默斯,ALKS,阿尔凯默斯股票,阿尔凯默斯股票老虎,阿尔凯默斯股票老虎国际,阿尔凯默斯行情,阿尔凯默斯股票行情,阿尔凯默斯股价,阿尔凯默斯股市,阿尔凯默斯股票价格,阿尔凯默斯股票交易,阿尔凯默斯股票购买,阿尔凯默斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔凯默斯(ALKS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔凯默斯(ALKS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}